Literature DB >> 19536733

The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men.

J G Schneider1, S Schiekofer, M von Eynatten, P Schlimmer, K A Dugi.   

Abstract

OBJECTIVE: To determine whether there is an independent association between the Pro12Ala polymorphism in the peroxisome proliferator-activated-receptor gamma2 (PPARgamma2)-gene and the extent of coronary artery disease in men. RESEARCH DESIGN AND METHODS: We determined the Pro12Ala polymorphism in the PPARgamma2 gene in 240 male patients undergoing elective coronary angiograpy, and quantitated the degree of CAD by evaluating the extent-score which better correlates with known risk factors than other measures of CAD.
RESULTS: The presence of the 12Ala allele was significantly associated with higher CAD extent (r=0.27, p<0.01). CAD extent was also correlated with the extent of insulin resistance (HOMA, r=0.22, p<0.01), and age (r=0.16, p<0.05). Multivariate analysis revealed an independent association between the 12Ala allele PPARgamma2 with extent-score (beta=0.32, p<0.01).
CONCLUSIONS: The 12Ala allele in PPARgamma2 correlates with a significantly increased CAD extent in men, which suggest that lower activity of the transcription factor PPARgamma2 is associated with more severe CAD. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536733     DOI: 10.1055/s-0029-1216351

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  2 in total

Review 1.  PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease.

Authors:  Yongyan Song; Shujin Li; Chuan He
Journal:  Front Cardiovasc Med       Date:  2022-03-23

2.  β3-integrin Leu33Pro gain of function variant does not modulate inflammatory activity in human derived macrophages in diabetes.

Authors:  Philipp Helmer; Ellen Damm; Stephan Schiekofer; Kirsten Roomp; Jochen G Schneider
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.